Ashwath Jayagopal

Ashwath Jayagopal

Company: Kodiak Sciences

Job title: Executive Director - Discovery Medicine

Bio:

Ash Jayagopal is the Executive Director of Discovery Medicine at Kodiak Sciences in Palo Alto, California, where his team is developing the pipeline for therapy of retinal diseases including AMD, DR, and glaucoma.  These programs leverage Kodiak’s expertise in biopolymers, bioconjugates, and engineering of small and large molecule therapeutic modalities.  Dr. Jayagopal’s expertise includes drug and biomarker discovery for retinal diseases, as well as the development of clinically-relevant technologies for retinal imaging and drug delivery.  Prior to Kodiak, he was the Head of Molecular Pharmacology and Biomarkers in the Ophthalmology Division at Pharma Research and Early Development (pRED), F. Hoffmann – La Roche Ltd., in Basel, Switzerland, where his team developed several therapies now in clinical development for retinal diseases.  Prior to Roche, he was an NIH-funded Assistant Professor in the Departments of Ophthalmology and Visual Sciences at the Vanderbilt Eye Institute, and Molecular Physiology and Biophysics of Vanderbilt University Medical Center in Nashville, TN.  Dr. Jayagopal received his undergraduate (with honors) and doctoral degrees in Biomedical Engineering from Vanderbilt University, as well as an MBA from Indiana University (Kelley School of Business).  He has received the Roche Key Contributor Award, the Dolly Green Special Scholar Award from Research to Prevent Blindness, and a Junior Faculty Award from the American Diabetes Association for his research.

Seminars:

Chair Led Q&A: Latest Case Studies Tackling the VEGF Pathway 12:55 pm

Read more

day: Day Two

KSI-301: An antibody-biopolymer conjugate for extended durability in retinal diseases 12:30 pm

Biophysical and biochemical principles of Kodiak Sciences’ antibody-biopolymer conjugate (ABC) platform Leveraging precise engineering of ABCs to achieve improved clinical outcomes in wet AMD, DME, and retinal vein occlusion An overview of preclinical and clinical studies to-date involving KSI-301, the first ABC for retinal diseasesRead more

day: Day Two

Panel: Searching for Novel Therapeutic Targets – Addressing Developmental Challenges for New Drug Candidates in Wet AMD & DME 11:10 am

• Discussions around the challenges of investigating unique treatment mechanistic pathways in wet AMD and DME, which can improve on existing anti-VEGF approaches • How does the distinctive disease progression pathways of both wet AMD and DME present the opportunity for new target discovery? • What are the key development bottlenecks in target identification and…Read more

day: Day Two

Opening Remarks from the Chair 8:20 am

Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.